Table 2.
Antigen-specific IFNγ ELISPOT responses
| a | ||||
|---|---|---|---|---|
| Patient number | Antigen | Maximum antigen specific T cell frequency | Fold increase post:pre TroVax immunization | |
| Pre-TroVax immunization | Post TroVax immunization | |||
| 002 | CEF | 1/885 | 1/936 | 0.95 |
| 5T4 Pep #77 | ≤1/200,000 | 1/4,717 | ≥42.4 | |
| MVA | 1/1,404 | 1/616 | 2.3 | |
| 003 | CEF | 1/588 | 1/639 | 0.92 |
| 5T4 Pep #8 | ≤1/200,000 | 1/27,027 | ≥7.4 | |
| MVA | 1/6,250 | 1/581 | 10.8 | |
| 005 | CEF | 1/1,029 | 1/688 | 1.5 |
| 5T4 Pep #41 | ≤1/200,000 | 1/2,096 | ≥95.4 | |
| MVA | 1/1,477 | 1/628 | 2.4 | |
| 007 | CEF | 1/10,526 | 1/4,292 | 2.5 |
| 5T4 Pep # | ≤1/200,000 | ≤1/200,000 | – | |
| MVA | 1/1,408 | 1/1,028 | 1.4 | |
| 009 | CEF | 1/665 | 1/566 | 1.2 |
| 5T4 Pep #8 | ≤1/200,000 | 1/726 | ≥275 | |
| MVA | N/A | 1/1,147 | N/A | |
| 012 | CEF | 1/625 | 1/548 | 1.1 |
| 5T4 Pep #5 | ≤1/200,000 | 1/2,033 | ≥98.4 | |
| MVA | N/A | 1/1718 | N/A | |
| 014 | CEF | N/A | 1/626 | N/A |
| 5T4 Pep | ≤1/200,000 | ≤1/200,000 | – | |
| MVA | N/A | 1/633 | N/A | |
| 015 | CEF | ≤1/200,000 | ≤1/200,000 | – |
| 5T4 Pep #41 | ≤1/200,000 | 1/23,256 | 8.6 | |
| MVA | 1/853 | 1/659 | 1.3 | |
| 016 | CEF | 1/8,547 | 1/4,587 | 1.9 |
| 5T4 Pep #41 | ≤1/200,000 | 1/3,597 | 55.6 | |
| MVA | 1/2421 | 1/792 | 3 | |
| 017 | CEF | ≤1/200,000 | ≤1/200,000 | – |
| 5T4 Pep #13 | ≤1/200,000 | 1/25,000 | ≥4 | |
| MVA | 1/730 | 1/762 | 0.96 | |
| 018 | CEF | 1/3,205 | 1/3,448 | 0.93 |
| 5T4 Pep #1 | ≤1/200,000 | 1/1,792 | ≥112 | |
| MVA | 1/919 | 1/832 | 1.1 | |
| 019 | CEF | 1/932 | 1/733 | 1.3 |
| 5T4 Pep #9 | ≤1/200,000 | 1/22,222 | 9 | |
| MVA | 1/1,770 | 1/1,429 | 1.2 | |
| b | ||||
|---|---|---|---|---|
| Patient number | Sum maximum 5T4 polyclonal precursor frequencies | |||
| Time point (week) | Peptides alone | Time point (week) | Protein ± peptides | |
| 002 | X + 10 | 1/4,717 | 13 | 1/2,208 |
| 003 | X + 8 | 1/27,027 | X + 8 | 1/9,372 |
| 005 | X + 6 | 1/868 | X + 6 | 1/706 |
| 007 | Any | ≤1/200,000 | X + 6 | 1/626 |
| 009 | 4 | 1/243 | 4 | 1/243 |
| 012 | X + 2 | 1/217 | X + 2 | 1/192 |
| 014 | Any | ≤1/200,000 | Any | ≤1/200,000 |
| 015 | 19 | 1/23,256 | 19 | 1/23,256 |
| 016 | X + 2 | 1/3,597 | X + 2 | 1/3,597 |
| 017 | X + 2 | 1/25,000 | X + 2 | 1/25,000 |
| 018 | X + 10 | 1/1050 | X + 6 | 1/625 |
| 019 | 19 | 1/22,222 | 19 | 1/22,222 |
aDetails the maximum antigen-specific T cell frequencies detected at baseline (pre-TroVax) and post-TroVax immunization following stimulation of patients’ PBMCs with the CEF positive control peptide pool, 5T4 peptide pools and MVA. The fold increase in antigen-specific T cell frequency following TroVax immunization is tabulated
bIllustrates the maximum 5T4 specific responses detected at any time point to ≥1 5T4 peptide pool or 5T4 peptide(s) plus protein (i.e. the sum of individual responses at one time point)